Communication Aids for Disabled (TDD)

Equipment that provides mentally or physically disabled persons with a means of communication. The aids include display boards, typewriters, cathode ray tubes, computers, and speech synthesizers. The output of such aids includes written words, artificial speech, language signs, Morse code, and pictures.

Also Known As:

TDD; Speech Synthesizers; Communication Board; Speech Synthesizer; Telecommunications Devices for the Deaf; TTY Telephone; Text Telecommunication; Text Telecommunication Devices; Text Telephone; Synthesizer, Speech; Synthesizers, Speech; TTY Telephones; Telecommunication Device, Text; Telecommunication Devices, Text; Telecommunication, Text; Telecommunications, Text; Text Telecommunication Device; Text Telecommunications; Text Telephones; Augmentative and Alternative Communications Systems; Communication Aids for Handicapped; Communication Boards

Networked: 229 relevant articles (19 outcomes, 21 trials/studies)

Relationship Network

Therapy Context: Research Results

Equipment and Supplies
- Self-Help Devices: 1620
  - Communication Aids for Disabled: 229

Experts

1.	Fischer, Philip R: 3 articles (02/2024 - 01/2020)
2.	Ehsan, Saad A: 3 articles (01/2023 - 10/2022)
3.	Lalani, Seema R: 3 articles (01/2023 - 10/2022)
4.	Li, Na: 3 articles (01/2023 - 01/2018)
5.	Miyake, Christina Y: 3 articles (01/2023 - 10/2022)
6.	Zhang, Lilei: 3 articles (01/2023 - 10/2022)
7.	Mathioudakis, Nestoras: 3 articles (12/2022 - 08/2016)
8.	Ge, Rui: 3 articles (04/2022 - 08/2015)
9.	Kuroda, Akio: 3 articles (02/2022 - 11/2012)
10.	Matsuhisa, Munehide: 3 articles (02/2022 - 11/2012)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2023 - "As an alternative to traditional oral and intravenous injections with limited efficacy, transdermal drug delivery (TDD) has shown great promise in tumor treatment. " 05/01/2024 - "In this cross-sectional study of patients with cancer and SARS-CoV-2, racial and ethnic inequities existed in TDD throughout the pandemic; however, the disproportionate burden among racially and ethnically minoritized patients with cancer varied across SARS-CoV-2 waves. " 05/01/2024 - "In multivariable analyses, non-Hispanic Black (third wave: aPR, 1.56; 95% CI, 1.31-1.85) and Hispanic or Latinx (third wave: aPR, 1.35; 95% CI, 1.13-1.62) patients with cancer were more likely to experience TDD compared with non-Hispanic White patients during the first year of the pandemic. " 05/01/2024 - "To evaluate TDD associations with race and ethnicity, adjusted prevalence ratios (aPRs) were estimated using multivariable Poisson regression, accounting for nonindependence of patients within clinics, adjusting for age, sex, body mass index, comorbidities, cancer type, cancer extent, and SARS-CoV-2 severity (severe defined as death, hospitalization, intensive care unit admission, or mechanical ventilation). " 05/01/2024 - "TDD was defined as any cancer treatment postponed more than 2 weeks or cancelled with no plans to reschedule. "
2.	Pain (Aches) 01/01/2014 - "All the subjects performed the exercise treadmill test, according to the Gardner protocol, at the beginning of the study, after 12 weeks and after 24 weeks, at the end of the study and were measured: the time to pain onset (TDC) and the time to maximum pain onset (maximum walking time=TDD). " 03/01/2024 - "TDD has been used in different pain syndromes with only limited reports in CP. " 01/01/2023 - "Furthermore, TDD hazard ratios numerically favored T-DXd over T-DM1 in all prespecified variables of interest including pain, suggesting T-DXd may delay time until health-related QoL deterioration compared with T-DM1. " 01/01/2022 - "Similarly, there were no statistically significant differences between groups in outcomes at 12 months: >50% reduction in NRS leg pain (PDD vs. TDD)=51% (95% CI 41%-60%) versus 40% (95% CI: 30%-49%); >30% ODI improvement (PDD vs. TDD)=42% (95% CI 32%-51%) versus 30% (95% CI: 21%-39%). " 01/01/2022 - "When using an intention to treat analysis with those lost to follow-up and requiring a second procedure counting as failures, there were no statistically significant difference between the two treatment groups in the primary and secondary outcomes at 6 months: >50% reduction in NRS leg pain (PDD vs. TDD)=67% versus 65%; >30% ODI improvement (PDD vs. TDD)=57% versus 55%. "
3.	Type 2 Diabetes Mellitus (MODY) 01/01/2020 - "Ninety-two poorly controlled type 2 diabetes patients aged 20-80 years with HbA1c ≥7.5% (58 mmol/mol) in the previous three months were randomly assigned to a 90 g/d LCD r traditional diabetic diet (TDD). " 01/01/2016 - "The regression formula was significantly more accurate for patients with type 2 diabetes overall, but the TDD-M estimate was marginally safer. " 05/01/2015 - "There is a steady decline of TDD after euglycemia is achieved in patients with newly diagnosed type 2 diabetes treated with CSII, and ΔTDD is associated with a better long-term glycemic outcome." 01/01/2020 - "This study was performed to evaluate the change in glycemic control (A1C) and insulin total daily dose (TDD) after switching to V-Go wearable insulin delivery device in a type 2 diabetes population with suboptimal control using conventional insulin delivery regimens. " 06/01/2016 - "To examine the influence of baseline U-100 insulin total daily dose (TDD) on clinical outcomes in severely insulin-resistant patients with inadequately controlled type 2 diabetes treated with human regular U-500 insulin (U-500R) from the perspective of current dosing recommendations. "
4.	Body Weight (Weight, Body) 01/01/2022 - "Body weight increased by + 4.8 kg and TDD by 16% at three years. " 01/01/2020 - "The results showed that Lf-Doxo-MMNPs, in addition to enhancing anticancer effects in vitro, resulted in a significant increase in body weight, TGI, and targeted drug delivery (TDD). " 09/01/2019 - "Each participant's HbA1c, body weight, and TDD were recorded prior to initiation of GLP-1RA therapy and at the 3, 6, and 12-month time points while on combination therapy. " 02/01/2018 - "To achieve HbA1c ≤7.5 in patients with T1D, TDD should be calculated based on body weight, and the %TBD should be set at 30% in the Japanese population." 02/01/2018 - "In the well-controlled group, TDD was correlated with body weight ( R = 0.51), BMI ( R = 0.44), body surface area ( R = 0.41), and TBD ( R = 0.73; P < 0.01 for all), but TBD was not correlated with BMI or body surface area. "
5.	Hypoglycemia (Reactive Hypoglycemia) 06/01/2016 - "Both TID and BID U-500R were efficacious and safe across TDD subgroups, though higher hypoglycemia rates were observed in higher-dose, treatment-pooled subgroups. " 12/01/2022 - "Inpatient insulin doses of 40% of home TDD or ≤ 0.6 unit/kg were not associated with increased hypoglycemia risk. " 12/01/2022 - "For the outcome of hypoglycemia, significantly higher odds were observed when non-fasting patients received an inpatient TDD that was either > 40% of their home TDD or > 0.6 unit/kg/d of insulin. " 11/01/2022 - "Secondary outcomes included change in weight and total daily dose (TDD) of insulin and incidence of hypoglycemia and other adverse effects (AEs). " 11/01/2021 - "No differences were observed in basal insulin TDD and hypoglycemia. "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Dichlorodiphenyldichloroethane (DDD)
3.	Hemoglobins (Hemoglobin)
4.	Opioid Analgesics (Opioids)
5.	Ethiodized Oil (Ethiodol)
6.	Glucose (Dextrose)
7.	Long-Acting Insulin (Insulin, Long Acting)
8.	Metformin (Glucophage)
9.	Liraglutide
10.	Short-Acting Insulin

Related Therapies and Procedures

1.	Decompression
2.	Therapeutics
3.	Electrocoagulation (Electrocautery)
4.	Peritoneal Dialysis
5.	Ligation